

# About OMICS Group


OMICS Group International is an amalgamation of [Open Access publications](#) and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology 'Open Access', OMICS Group publishes 400 online open access [scholarly journals](#) in all aspects of Science, Engineering, Management and Technology journals. OMICS Group has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women.

Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS Group also organizes 300 [International conferences](#) annually across the globe, where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions.

# About OMICS Group Conferences

OMICS Group International is a pioneer and leading science event organizer, which publishes around 400 open access journals and conducts over 300 Medical, Clinical, Engineering, Life Sciences, Pharma scientific conferences all over the globe annually with the support of more than 1000 scientific associations and 30,000 editorial board members and 3.5 million followers to its credit.

OMICS Group has organized 500 conferences, workshops and national symposiums across the major cities including San Francisco, Las Vegas, San Antonio, Omaha, Orlando, Raleigh, Santa Clara, Chicago, Philadelphia, Baltimore, United Kingdom, Valencia, Dubai, Beijing, Hyderabad, Bangalore and Mumbai.



NOS3, APOE, TNF, MTHFR, IL6, ACE, VEGFA, ESR1, ADIPOQ, MMP9, CRP, IL1B, PTGS2, TGFB1, TLR4, NPPB, IGF1, HIF1A, ITGB3, LEP, CXCL8, GSTM1, AGTR1, EDN1, CXCL12, CCL2, LPL, ADRB2, MAPK1, APOA1, SOD1, GHRL, RETN, INS, NOS2, TNFRSF11B, SOD2, HMGB1, FGF2, TNNT2, MIF, FTO, GH1, EPO, NOTCH3, TNNI3, HSPA1A, ENPP1, NOS1, SREBF1, PDGFRB, ANGPT1, KL, AQP4, SGK1, FABP4

# Phenotype segregation network analysis (PSNA) identifies chronic complex disease triggers in substructured human groups



Fatimah L.C. Jackson, Ph.D.  
Professor of Biology  
Director, W. Montague Cobb Research Laboratory  
Howard University  
Washington, DC 20059  
USA



# Thanks to my collaborators

**Dr. Latifa Jackson**, computational biologist


Department of Biomedical Sciences

Drexel University

Philadelphia, PA

USA

[lfj27@drexel.edu](mailto:lfj27@drexel.edu)



**Dr. Raouf Ghomrasni**, mathematician

African Institute for Mathematical Sciences

6-8 Melrose Road

7945 Muizenberg

South Africa

[raouf@aims.ac.za](mailto:raouf@aims.ac.za)




# Complex chronic diseases

- 36,000,000 deaths by 2015
- 30% cardiovascular disease
- 13% cancer (especially breast, colon, prostate)
- 7% chronic respiratory disease
- 2% diabetes

- **Chronic kidney disease** (chronic kidney failure) describes the gradual loss of kidney function resulting in the build up of dangerous levels of fluid, electrolytes and toxins in the body.




# Ethnogenetic Layering




# Ethnic Groups

es:



## GIS World Model




2003 Ethnogenetic Layering: A Novel Approach to Determining Environmental Health Risk Potentials Among Children from Three US Regions. *Journal of Children's Health*, 1(3):369-386. <http://www.healthcare.com/doi/abs/10.3109/15417060390254355>

2004 Human genetic variation and health: Ethnogenetic layering as a way of detecting relevant population substructuring. *British Medical Bulletin*. 69:215-235. <http://www.bmjournals.org/content/69/1/215.short>

2006 Illuminating cancer health disparities using ethnogenetic layering (EL) and phenotype segregation network analysis (PSNA). *J Cancer Education* 21(1):69-79. <http://ukpmc.ac.uk/abstract/MED/1702>

2008 Ethnogenetic Layering (EL): An alternative to the traditional race model in human variation and health disparity studies. *Annals of Human Biology* Mar-Apr 35(2):121-144. <http://www.healthcare.com/doi/pdf/10.1080/03014460801941752>

# Ethnogenetic Layering General Methods





# What is PSNA?

## Phenotype Segregation Network Analysis

Relies on high throughput assessments of MEGs by environmental variables and ancestral genetics and then by phenotypic traits.

Permits the representation (i.e., networks) of relationships between phenotypic traits and MEGs.

Serves as a “pointer” to identify which MEGs have the highest probability of revealing the underlying causes of specific disease-associated phenotypic correlations.

## Phenotype Segregation Network Analysis (PSNA)




**Based on ethnogenetic analysis, microethnic groups are identified within each geographical regional area of interest.**

**FIGURE 1. Ethnogenetic layering sorts a pool of MEGs by geographical region. This initial step can be contrasted with the traditional pattern of lumping MEGs into macroethnic or racial clusters across geographical space and ignoring both within-group substructure and between-group disease-relevant commonalities.**

## Traditional Macroethnic “racial” groupings of Microethnic Groups of Interest


African Americans



European Americans




Native Americans



Classical clumping of diverse microethnic groups into macroethnic clusters. The process results in reduced recognition of intragroup diversity.

**Figure 2. Aggregated microethnic groups in the traditional racial model. When microethnic groups are lumped based upon classic racial designations, “racial” groups are found in each geographical region of interest but the nuanced analysis of local genetic, cultural, and environmental factors in disease causation is compromised.**

# Environmental Sources of Genotype-Phenotype Discontinuity




These factors provide additional sources of variation to the expressed genotype (the phenotype) and modify the coded genotypic message. While these factors are not genetic, they can behave in ways that influence gene expression over generations.

Table 1: Environmental variables and ancestral genetic factors used to sort MEGs.

MEG	Abiotic environmental variables	Biotic environmental variables	Sociocultural environmental variables	Ancestral genetic factors
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				

Construction of a MEGs affinity matrix based upon assessment of the relevant environmental and ancestral genetic traits of interest:



Lines between MEGs indicate shared phenotypic traits. The darker the line, the greater the number of shared traits between the demarcated groups.

**Figure 3. Affinity matrix of microethnic groups based upon presentation patterns of exposure to relevant environmental traits and ancestral genetic backgrounds. Heavy bars represent two or more traits in common while thin bars represent only one trait in common (based upon data presented in Table 1).**

<b>CKD- Associated Phenotypic Trait</b>	<b>Recent Reference</b>
---	-------------------------

**Tables 2.0 – 2.3 A subsample of 50 phenotypic traits associated with chronic renal disease for use in PSNA.**

# -Associated Phenotypes for PSNA

diabetes	Bjornstad et al 2014; Gosmanov et al 2014; Prakash 2013
cognitive impairment	Pulignano et al 2014; Seidel et al 2014; Miwa et al 2014
plasma miRNA levels	Szeto 2014; Zununi Vahed et al 2014
urinary proteome biomarkers	Gu et al 2014; Caliskan and Kiryluk 2014
glomerular filtration rate (est.)	Rausch et al 2014; Ajayi et al 2014; Levey et al 2014
heart failure	Segall et al 2014; Chawla et al 2014
hypothyroidism	Paudel 2014; Prajapati et al 2013
5-dihydroxytryptamine urolithiasis	Ceballos-Picot et al 2014
platelet receptor alpha	Somers and O'Shannessy, 2014
speech and lung function	Palamidas et al 2014



## D-Associated Phenotypes for PSNA

<b>Glycosylated hemoglobin A1c</b>	Shipman et al 2014
<b>Proteinuria</b>	Cvitković et al 2014
<b>Left atrial remodeling</b>	Sciacqua et al 2014
<b>Health literacy</b>	Chow et al 2014; Roomizadeh et al 2014; Lopez-Vargas et al 2014; Burke et al 2014
<b>Renal Anemia</b>	Kelepouris and Kalantar-Zadeh 2014; Dousdampanis et al 2014
<b>Vascular calcification</b>	Knežević et al 2014
<b>Urinary electrolytes/conductivity</b>	Wang et al 2014; Blann 2014
<b>Depression</b>	Bantovich et al 2014; Knuth et al 2014; Schell et al 2014
<b>Serum creatine</b>	Proule et al 2014
<b>Osteoporosis and osteopenia</b>	Miller 2014; Gupta 2014; Salam et al 2014; Khan et al 2014
<b>Cystatin C</b>	Vigil et al 2014; Fox et al 2014; Jeon et al 2013; Li et al 2013
<b>Renal Inflammation</b>	Wu et al 2014; Kelepouris and Kalantar-Zadeh 2013
<b>Atrial fibrillation</b>	Buiten 2014
<b>Dietary complements</b>	Dori et al 2014; Hsieh et al 2014; Steiber 2014
<b>Carotid artery stenting</b>	AbuRahma et al 2014; Hakimi et al 2014

## CKD-Associated Phenotypes for PSNA

<b><i>APOL1</i> polymorphism</b>	Freedman et al 2014; Cooke Bailey et al 2014
<b>Platelet reactivity</b>	Mangiacapra et al 2014
<b>Chronological age</b>	Tonelli and Riella 2014; Nitta et al 2013
<b>Serum complement C3</b>	Molad et al 2014
<b>Physical function and gait speed</b>	Painter and Marcus 2013; Baumgaertel et al 2014
<b>Albuminuria</b>	Komenda et al 2014; Liu et al 2014; Abdelmalek et al 2014
<b>Pleural effusion</b>	Ray et al 2013
<b>Periodontal disease</b>	Mohangi et al 2013
<b>Oxidative stress (mitochondria)</b>	Daehn et al 2014
<b>Auditory acuity</b>	Lopez et al 2014; D'Andrea et al 2013
<b>Nephrotoxic exogenous agents</b>	Roxanas et al 2014; Ingrassiotta et al 2014; Akilesh et al 2014; Sánchez-González et al 2013
<b>Cardiovascular disease</b>	Cai et al 2013; Ahmadi et al 2014; Chawla et al 2014
<b>Dyslipidemia</b>	Omran et al 2013
<b>Obesity</b>	Park et al 2014

## KD-Associated Phenotypes for PSNA

<b>Insomnia and sleep apnea</b>	Ahmed et al 2013
<b>Microvascular function</b>	Imamura et al 2014
<b>Nutritional status</b>	dos Santos et al 2013
<b><i>WT1</i> or <i>TRIB3</i> polymorphisms</b>	Lipska et al 2014; Ding et al 2014
<b>Treatment resistant hypertension</b>	Tanner et al 2014
<b>Renal histology</b>	Wijetunge et al 2013; Tarnoki et al 2013
<b>Dopamine D2 receptor polymorphism</b>	Jiang et al 2014
<b>Inflammatory myopathy</b>	Couvrat-Desvergnés et al 2014
<b>FSGS and nephropathic biomarkers</b>	Nafar et al 2014 ; Nkuipou-Kenfack et al 2014
<b>Diastolic function</b>	Farshid et al 2013

## Production of a correlation matrix of the phenotypic trait interrelationships

Phenotypic traits without added rotating values	Phenotypic traits with added rotating values based upon Poisson or Gaussian distribution						
	Trait 1	Trait 2	Trait 3	Trait 4	Trait 5	Trait 6	Trait N
Trait 1	--	Z					
Trait 2	Z	--					
Trait 3			--			Z	
Trait 4				--	Z		
Trait 5				Z	--		
Trait 6			Z			--	
Trait N							--

Z indicates presence of significant correlation between specific phenotypic traits in overall population studied.

**Figure 4. A simplified version of the correlational matrix in PSNA for the traits listed in Tables 2.0-2.1. Z represents a statistically significant correlation between traits (p<0.05).**

## Identification of specific phenotypic traits of interest and evaluation of each microethnic group for these traits

Phenotypic traits of interest	Microethnic groups (MEGs) of interest											
	1	2	3	4	5	6	7	8	9	10	11	12
Trait 1	X	X					X				X	
Trait 2	X	X										
Trait 3				X						X	X	
Trait 4		X				X						
Trait 5						X		X				
Trait 6				X						X	X	
Trait N												

Figure 5. Validated phenotypic traits are evaluated in each MEG of interest and the results compared. X indicates the presentation of a specific phenotypic trait. MEGs with similar phenotypic presentations of the chronic disease of interest are studied further. Notice that MEGs 3, 5, 9, and 12 do not display any of the phenotypic traits under study.

# Identification of most relevant microethnic groups for investigations of statistically linked phenotypic traits


Paired traits indicate an association between traits in select MEGs

Phenotypic traits of interest	Microethnic groups (MEGs) of interest											
	1	2	3	4	5	6	7	8	9	10	11	12
Trait 1	X	X					X				X	
Trait 2	X	X										
Trait 3			X						X	X		
Trait 4		X				X						
Trait 5						X		X				
Trait 6			X							X	X	
Trait N												

5. Identification of MEGs for subsequent genetic, cultural, and/or environmental analysis in chronic disease. In the case CKD-associated traits, microethnic groups 1 and 2 display linked phenotypic traits 1 and 2. Microethnic groups 4, 10, and 11 display linked phenotypic traits 3 and N and microethnic group 6 displays linked phenotypic traits 4 and 5.


## Identification of most promising microethnic groups for subsequent studies of disease association factors

Using P3NA, significantly linked chronic disease-related traits and the microethnic groups within whom they are expressed. Note lack of racial concordance with correlated traits.



**7. Re-association of correlated traits with MEGs and “racial” identifications of identified MEGs. The lack of agreement (see Figure 4) with the traits suggests that regional genetic, cultural, and/or environmental influence may be playing more important roles than “race” *per se* in disease causation.**

# Step Algorithm for PSNA



**Investigate the likely underlying causes of specific chronic disease associated phenotypic correlations by environmental and ancestral genetic variables**



## Applications of PSNA

PSNA should prove useful in a number of applications in the identification of risk factors in complex chronic diseases. For example, these include:

**Ranking of classic diagnostic procedures and techniques for specific subgroups.** In chronic disease studies, classic diagnosis and treatment procedures often find human biodiversity problematic. The recognition of substructure in macroethnic groups (=races) can, with PSNA, be used productively to provide more sensitive disease recognition strategies.

**Improved specificity of treatment regimes for particular individuals and groups within targeted MEGs** Unlike “individualized medicine” which does not integrate social, cultural, and environmental factors into diagnosis and treatment, or “race medicine” which ignores within group variability, PSNA focuses on the microethnic group level of analysis. This means that chronic disease intervention strategies can be localized to the specific social, cultural, environmental, and ancestral dynamics of regional MEGs.

**Increased resolution of roles of social, cultural, and biological contributors to existing disparities.** Integrative biology is particularly well poised to quantify the contributions of social, biological, and biocultural contributors to complex chronic disease health disparities. PSNA reduces some of the ambiguity in these quantifications by identifying the MEGs most likely to express specific correlated phenotypes. This makes association studies much less of a “shot in the dark”. Our procedure also makes for more informed design in clinical trials/medical research.

**Integration of sophisticated genetic, sociocultural, and environmental data in disease assessments.** Finally the data on disease assessment must be meaningfully integrated for incorporation into local models of chronic disease. PSNA provides the context for these integrations and reduces the tendency in race-based studies to overextend research results to other MEGs with little more in common with the study group than a remote shared past.

## Limitations of PSNA

Important independent phenotypic traits that are not linked to other phenotypic traits could be missed in our PSNA calculations.

Causation is not specifically implied by our analysis; PSNA simply points to statistical matches in the phenotypes examined and identifies the MEGs harboring those phenotypes. Causation requires additional analyses.

It is possible that in some cases, no MEGs will correspond with statistically correlated traits. However, our technique still recognizes geographic 'clusters' of people of equal public health significance.

Once the list of 100 phenotypic traits is finalized, the discovery of new phenotypic traits would require that the number of correlations performed would have to be increased to include these in the analyses. On the other hand, if some of the studied phenotypic traits from the finalized list are subsequently discounted, the number of correlations undertaken would have to be decreased.

MEGs have to be periodically revisited since these are dynamic groups and all aspects of their composition are potentially undergoing change, particularly given the magnitude of recent immigration and ongoing assimilation.

PSNA is based on a nonreductionist, integrative platform. As such, its statistical analysis and application includes many different kinds of data, for example, behavioral, demographic, toxicological, pharmacologic, genetic, dietary, historical, etc.

## Why is this research important?

Geneticists have been handicapped by (unknown) population substructure in the search for robust and consistent disease-associated genes.

Many of our GWAS results are of little clinical significance across population groups.

As health disparities grow, we need computation-assisted methods to sort through the high degree of variability in heterogeneous human groups to accurately identify the biological bases for these inequities.



*Thank you for your  
attention.*

# Let Us Meet Again

We welcome you all to our future conferences of OMICS Group  
International

Please Visit:

[www.omicsgroup.com](http://www.omicsgroup.com)

[www.conferenceseries.com](http://www.conferenceseries.com)

[www.pharmaceuticalconferences.com](http://www.pharmaceuticalconferences.com)